Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Blood (2014) 124 (21): 131.

https://doi.org/10.1182/blood.V124.21.131.131

Published: 2014

Journal Articles

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

Peter Rhein, PhD, Rita Mitlohner, Renate Kirschner-Schwabe, PhD, Christian Hagemeier, MD, PhD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Iduna Fichtner, PhD, Richard Ratei, MD, Wolf-Dieter Ludwig, Leonid Karawajew, PhD

Blood (2011) 118 (21): 752.

https://doi.org/10.1182/blood.V118.21.752.752

Published: 2011

Journal Articles

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Gunnar Cario, MD, Rita Mitlohner, Martin Zimmermann, PhD, Renja Romey, Peter Rhein, PhD, André Schrauder, MD, Anja Moericke, MD, Jean-Pierre Bourquin, MD, PhD, Wolf-Dieter Ludwig, MD, Richard Ratei, MD, Martin Schrappe, MD, Leonid Karawajew, PhD, Martin Stanulla, MD, MSc

Blood (2011) 118 (21): 742.

https://doi.org/10.1182/blood.V118.21.742.742

Published: 2011

Journal Articles

Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002

Arend von Stackelberg, MD, Junko Yamanaka, MD, Gabriele Escherich, MD, Cornelia Eckert, PhD, Richard Ratei, MD, Johann K. Hitzler, MD, Georg Mann, MD, Lucie Sramkova, MD, Jean-Pierre Bourquin, MD, PhD, Martin Schrappe, MD, Günter Henze, MD

Blood (2011) 118 (21): 871.

https://doi.org/10.1182/blood.V118.21.871.871

Published: 2011

Journal Articles

Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)

Peter Rhein, Richard Ratei, MD, Rita Mitlohner, Giuseppe Basso, MD, Giuseppe Gaipa, MD, Michael N Dworzak, MD, PhD, Martin Stanulla, MD, Martin Schrappe, MD, Wolf-Dieter Ludwig, MD, Leonid Karawajew, PhD

Blood (2008) 112 (11): 2526.

https://doi.org/10.1182/blood.V112.11.2526.2526

Published: 2008

Journal Articles

Glucocorticoid Therapy Targets Proliferation, Differentiation and Bcl-2 Dependent Survival Signaling in ALL Blasts.

Peter Rhein, Stefanie Scheid, Richard Ratei, MD, Christian Hagemeier, PhD, MD, Karl Seeger, PhD, MD, Renate Kirschner-Schwabe, PhD, Martin Schrappe, MD, Rainer Spang, PhD, Wolf-Dieter Ludwig, MD, Leonid Karawajew, PhD

Blood (2006) 108 (11): 1841.

https://doi.org/10.1182/blood.V108.11.1841.1841

Published: 2006

Journal Articles

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

Nicola Goekbuget, MD, Renate Arnold, MD, Johannes Atta, MD, Patrick Brück, MD, Stella Hermann, MD, Heinz Horst, MD, Mustafa Kondakci, MD, Roswitha Kotthoff, Oliver Ottmann, MD, Thorsten Raff, MD, Richard Ratei, MD, Mathias Schmid, MD, Michael Stadler, MD, Dieter Hoelzer, MD, PhD

Blood (2005) 106 (11): 150.

https://doi.org/10.1182/blood.V106.11.150.150

Published: 2005

Journal Articles

Gene Expression in Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL Displays a Common Shift towards Terminally Differentiated B Cells and a Cytoreduction-Associated Impairment of the Translational Machinery.

Blood (2005) 106 (11): 537.

https://doi.org/10.1182/blood.V106.11.537.537

Published: 2005

Journal Articles

Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.

Anja Möricke, MD, Richard Ratei, MD, Wolf-Dieter Ludwig, MD, PhD, Jochen Harbott, PhD, Arndt Borkhardt, MD, PhD, Susanne Viehmann, PhD, Martin Zimmermann, PhD, Helmut Gadner, MD, PhD, Hansjörg Riehm, MD, PhD, Martin Schrappe, MD, PhD

Blood (2004) 104 (11): 1957.

https://doi.org/10.1182/blood.V104.11.1957.1957

Published: 2004

Journal Articles

Feasibility of Multicentric Assessment of MRD in All by Flow-Cytometry: Standardization and Experience of the I-BFM-ALL FCM-MRD Study Group.

Giuseppe Gaipa, PhD, Marinella Veltroni, PhD, Richard Ratei, MD, Wolf-Dieter Ludwig, MD, Andrea Biondi, MD, Giuseppe Basso, MD, Michael N. Dworzak, MD

Blood (2004) 104 (11): 1079.

https://doi.org/10.1182/blood.V104.11.1079.1079

Published: 2004

NARROW

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002

Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)

Glucocorticoid Therapy Targets Proliferation, Differentiation and Bcl-2 Dependent Survival Signaling in ALL Blasts.

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

Gene Expression in Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL Displays a Common Shift towards Terminally Differentiated B Cells and a Cytoreduction-Associated Impairment of the Translational Machinery.

Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.

Feasibility of Multicentric Assessment of MRD in All by Flow-Cytometry: Standardization and Experience of the I-BFM-ALL FCM-MRD Study Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only